Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study

Ishiguro, Yui; Sakihama, Hideyasu; Yoshida, Tadashi; Ichikawa, Nobuki; Homma, Shigenori; Fukai, Moto; Kawamura, Hideki; Takahashi, Norihiko; Taketomi, Akinobu

doi:10.1245/s10434-020-08827-6

Cited by 10 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Li et al [ 73 ] reported that the patients with worsened medical conditions showed a high rate of mesenchymal CTCs. Moreover, Ishiguro et al [ 46 ] showed that CTCs alive should be evaluated to predict the metastasis. Also, they found that the approximate estimation of estimating the time of recurrence is possible by dividing patients according to the presence of CTCs before and after the treatment.…”

Section: Discussionmentioning

confidence: 99%

“…In our opinion, if cytological methods are used to isolate CTC in GC patients, it is better to use mesenchymal markers when a patient is in advanced stage because epithelial markers may be ignored in a population of CTCs that have undergone EMT. Therefore, the use of mesenchymal markers (such as N-cadherin,…) for the cellular heterogeneity of CTCs is useful in these conditions [ 46 ], although the cell search method still proves acceptable results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis

Eskandarion,

Eskandarieh,

Tutunchi

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Investigating the role of circulating tumor cells (CTCs) and their characteristics is still controversial in patients with gastric cancer (GC). Therefore, in this study, to provide a comprehensive review and meta-analyses of the literature on association of CTCs with gastric cancer, Scopus, Web of Science, Embase, and Medline were searched for systematic reviews and meta-analyses conducted during February 2022 using the keywords. Risk of bias, hazard ratios (HRs), and risk differences (RD) were assessed. Forty-five studies containing 3,342 GC patients from nine countries were assessed. The overall prevalence of CTC in GC was 69.37% (60.27, 77.78). The pooled result showed that increased mortality in GC patients was significantly associated with positive CTCs, poor overall survival (HR = 2.73, 95%CI 2.34–3.24, p < 0.001), and progression-free survival rate (HR = 2.78, 95%CI 2.01–3.85, p < 0.001). Subgroup analyses regarding markers, detection methods, treatment type, presence of distance metastasis, presence of lymph node metastasis, and overall risk of bias showed significant associations between the groups in terms of the incidence rates of CTCs, OS, and PFS. In addition, the results of risk differences based on sampling time showed that the use of the cell search method (RD: − 0.19, 95%CI (− 0.28, − 0.10), p < 0.001), epithelial marker (RD: − 0.12, 95%CI (− 0.25, 0.00), p 0.05) and mesenchymal markers (RD: − 0.35, 95%CI (− 0.57, − 0.13), p 0.002) before the treatment might have a higher diagnostic power to identify CTCs and also chemotherapy treatment (RD: − 0.17, 95%CI (− 0.31, − 0.03), p 0.016) could significantly reduce the number of CTCs after the treatment. We also found that the risk differences between the clinical early and advanced stages were not statistically significant (RD: − 0.10, 95%CI (− 0.23, 0.02), P 0.105). Also, in the Lauren classification, the incidence of CTC in the diffuse type (RD: − 0.19, 95%CI (− 0.37, − 0.01), P0.045) was higher than that in the intestinal type. Meta-regression analysis showed that baseline characteristics were not associated with the detection of CTCs in GC patients. According to our systematic review and meta-analysis, CTCs identification may be suggested as a diagnostic technique for gastric cancer screening, and the outcomes of CTC detection may also be utilized in the future to create personalized medicine programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis

Eskandarion,

Eskandarieh,

Tutunchi

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…In this regard, it has been shown that in GC the presence of detectable CTCs in the blood is an independent predictor of reduced survival [171,172]. Moreover, the CTC count after therapy predicts therapeutic response, recurrence and survival [173][174][175][176]. Particularly, CTCs expressing CD44 are the ones that predict GC prognosis and metastasis [101], which moreover, exhibit stem properties such as chemoresistance and multipotency ex vivo [89].…”

Section: Different Approaches and Concerns In The Targeting Of Gcscsmentioning

confidence: 99%

Impact of Cancer Stem Cells on Therapy Resistance in Gastric Cancer

Otaegi-Ugartemendia

Matheu

Carrasco‐García

2022

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is the fourth leading cause of cancer death worldwide, with an average 5-year survival rate of 32%, being of 6% for patients presenting distant metastasis. Despite the advances made in the treatment of GC, chemoresistance phenomena arise and promote recurrence, dissemination and dismal prognosis. In this context, gastric cancer stem cells (gCSCs), a small subset of cancer cells that exhibit unique characteristics, are decisive in therapy failure. gCSCs develop different protective mechanisms, such as the maintenance in a quiescent state as well as enhanced detoxification procedures and drug efflux activity, that make them insusceptible to current treatments. This, together with their self-renewal capacity and differentiation ability, represents major obstacles for the eradication of this disease. Different gCSC regulators have been described and used to isolate and characterize these cell populations. However, at the moment, no therapeutic strategy has achieved the effective targeting of gCSCs. This review will focus on the properties of cancer stem cells in the context of therapy resistance and will summarize current knowledge regarding the impact of the gCSC regulators that have been associated with GC chemoradioresistance.

show abstract

Circulating tumor cells in gastric cancer: developments and clinical applications

Deng,

Jiang,

Yan

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study

Cited by 10 publications

References 32 publications

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis

Impact of Cancer Stem Cells on Therapy Resistance in Gastric Cancer

Circulating tumor cells in gastric cancer: developments and clinical applications

Contact Info

Product

Resources

About